NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2043.40 55.40 (2.79%)

1.7M NSE+BSE Volume

High volume today

NSE 12 Sep, 2025 3:31 PM (IST)

93,333.2

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

13 Feb 2025, 12:00AM

2043.40

2.79%

Lupin (BUY): High-margin US region to have growth visibility till FY27

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

US sales cc quarterly run rate at its highest-ever level of US$ 235mn, expect to inch up to US$ 250mn in FY26E and US$ 280mn in FY27E

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

30 Dec 2024

2043.40

2.79%

Delay in approval for Amneal's gProAir an unexpected positive

Buy: Lupin Ltd.

Emkay

In Teva’s litigation with Amneal which blocked Amneal’s launch of gProAir, the US Court of Appeals had recently asked Teva to delist its patents in contention. While the ruling was expected to clear the way for Amneal’s launch of gProAir, Teva has now filed a petition seeking an en banc rehearing.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

16 Dec 2024

2043.40

2.79%

Lupin (BUY): Reduction in in-licence portfolio to increase margins

Buy: Lupin Ltd.

BOB Capital Markets Ltd.

LPC's domestic region in-licence portfolio fell from 15% in Q2FY24 to 12% in Q2FY25 and is expected to reduce further to ~10% by FY26

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

11 Nov 2024

2043.40

2.79%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We recommend a BUY rating with a target price of Rs 2,600/share.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

10 Nov 2024

2043.40

2.79%

Superlative margin performance; US reversal likely in 3Q

Buy: Lupin Ltd.

Target

Emkay

Lupin’s 2QFY25 EBITDA/Adj PAT were 18%/26% ahead of our estimates (the magnitude of beat was broadly similar vs street estimates).

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

09 Nov 2024

2043.40

2.79%

Lupin (BUY): In-line quarter; EBITDAM guidance increased to 25%

Buy: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

LPC's earnings were in line with our estimates but beat street's estimates. EBITDA margin was 23% in Q2FY25

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

08 Aug 2024

2043.40

2.79%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We have BUY on the Stock

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

07 Aug 2024

2043.40

2.79%

Strong Q1; complex products to drive growth

Buy: Lupin Ltd.

Target

Sharekhan

Q1FY2025 numbers were strong, beating our estimates on all fronts. Sales grew by 16% y-o-y to Rs. 5514 crore (9% above our estimates), on a 28% y-o-y growth in North America region to Rs. 2041 crore.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

07 Aug 2024

2043.40

2.79%

Strong beat; US/India drive earnings

Neutral: Lupin Ltd.

Target

Motilal Oswal

LPC delivered a strong earnings beat in 1QFY25, led by a superior show in key markets (US/India), lower R&D spending and a low tax rate.

Lupin Ltd.'s price crossed above 200Day SMA today

Lupin Ltd.

10 Jul 2024

2043.40

2.79%

Launches critical for sustenance of turnaround

Sell: Lupin Ltd.

Target

ICICI Securities Limited

Lupin’s recent success in US (sales grew ~34% YoY in FY24) is driven by its better regulatory track record and traction in inhalation portfolio. Share of inhalation products has risen from 25% of US sales in FY22 (USD 185mn) to 40% in FY24
(USD 326mn) post the launch of gSpiriva. In India, growth had been subdued due to the discontinuation of in-licensed brands (contribution down from 15% in FY23 to 11% in Q4FY24).

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Is Lupin Ltd. worth buying?

923 Votes:

Buy 72.81%

Sell 17.44%

Hold 9.75%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf